Compounds showing inhibitory activities against the NFκB pathways, such as JSH-23, might be considered promising pre-clinical agents to develop clinically oriented protocols to control the hyperinflammatory state of cystic fibrosis. The gene discussed is NFKB1; the disease is cystic fibrosis.